title: Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
abstract: Current dietary therapy for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency consists of fasting avoidance, and limiting long-chain fatty acid (LCFA) intake. This study reports the relationship of dietary intake and metabolic control as measured by plasma acylcarnitine and organic acid profiles in 10 children with LCHAD or TFP deficiency followed for 1 year. Subjects consumed an average of 11% of caloric intake as dietary LCFA, 11% as MCT, 12% as protein, and 66% as carbohydrate. Plasma levels of hydroxypalmitoleic acid, hydroxyoleic, and hydroxylinoleic carnitine esters positively correlated with total LCFA intake and negatively correlated with MCT intake suggesting that as dietary intake of LCFA decreases and MCT intake increases, there is a corresponding decrease in plasma hydroxyacylcarnitines. There was no correlation between plasma acylcarnitines and level of carnitine supplementation. Dietary intake of fat-soluble vitamins E and K was deficient. Dietary intake and plasma levels of essential fatty acids, linoleic and linolenic acid, were deficient. On this dietary regimen, the majority of subjects were healthy with no episodes of metabolic decompensation. Our data suggest that an LCHAD or TFP-deficient patient should adhere to a diet providing age-appropriate protein and limited LCFA intake (10% of total energy) while providing 10-20% of energy as MCT and a daily multi-vitamin and mineral (MVM) supplement that includes all of the fat-soluble vitamins. The diet should be supplemented with vegetable oils as part of the 10% total LCFA intake to provide essential fatty acids.
authors.affiliation: Departments of Pediatrics and Molecular and Medical Genetics, Oregon Health and Science University (OHSU), Mail code CDRC-F, P.O. Box 574, Portland, OR 97207-0574, USA.
authors.forename: Melanie B
authors.initials: MB
authors.lastname: Gillingham
authors.forename: William E
authors.initials: WE
authors.lastname: Connor
authors.forename: Dietrich
authors.initials: D
authors.lastname: Matern
authors.forename: Piero
authors.initials: P
authors.lastname: Rinaldo
authors.forename: Terry
authors.initials: T
authors.lastname: Burlingame
authors.forename: Kaatje
authors.initials: K
authors.lastname: Meeuws
authors.forename: Cary O
authors.initials: CO
authors.lastname: Harding
mesh_terms: D015094:3-Hydroxyacyl CoA Dehydrogenases / Q000172:deficiency*; D002331:Carnitine / Q000031:analogs & derivatives* / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004035:Diet Therapy / Q000379:methods; D002149:Energy Intake; D005227:Fatty Acids / Q000097:blood; D005260:Female; D006801:Humans; D007223:Infant; D008052:Lipid Metabolism, Inborn Errors / Q000178:diet therapy* / Q000378:metabolism*; D063989:Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase; D008297:Male; D008903:Minerals / Q000493:pharmacokinetics; D009097:Multienzyme Complexes / Q000172:deficiency; D016896:Treatment Outcome; D014815:Vitamins / Q000493:pharmacokinetics
chemical_list: D005227:Fatty Acids; D008903:Minerals; D009097:Multienzyme Complexes; D014815:Vitamins; C116917:acylcarnitine; D015094:3-Hydroxyacyl CoA Dehydrogenases; D063989:Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase; D002331:Carnitine